Cargando…

Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia

No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouzaid, Safiya, Tian, Haijun, Zhou, Huanxue, Kahler, Kristijan H., Harris, Michelle, Kim, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895443/
https://www.ncbi.nlm.nih.gov/pubmed/23229052
http://dx.doi.org/10.1007/s10597-012-9561-7
_version_ 1782299967791038464
author Abouzaid, Safiya
Tian, Haijun
Zhou, Huanxue
Kahler, Kristijan H.
Harris, Michelle
Kim, Edward
author_facet Abouzaid, Safiya
Tian, Haijun
Zhou, Huanxue
Kahler, Kristijan H.
Harris, Michelle
Kim, Edward
author_sort Abouzaid, Safiya
collection PubMed
description No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Multi-State Database (2004–2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs.
format Online
Article
Text
id pubmed-3895443
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-38954432014-01-24 Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia Abouzaid, Safiya Tian, Haijun Zhou, Huanxue Kahler, Kristijan H. Harris, Michelle Kim, Edward Community Ment Health J Original Paper No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Multi-State Database (2004–2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs. Springer US 2012-11-16 2014 /pmc/articles/PMC3895443/ /pubmed/23229052 http://dx.doi.org/10.1007/s10597-012-9561-7 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Abouzaid, Safiya
Tian, Haijun
Zhou, Huanxue
Kahler, Kristijan H.
Harris, Michelle
Kim, Edward
Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title_full Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title_fullStr Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title_full_unstemmed Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title_short Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
title_sort economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895443/
https://www.ncbi.nlm.nih.gov/pubmed/23229052
http://dx.doi.org/10.1007/s10597-012-9561-7
work_keys_str_mv AT abouzaidsafiya economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia
AT tianhaijun economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia
AT zhouhuanxue economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia
AT kahlerkristijanh economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia
AT harrismichelle economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia
AT kimedward economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia